SAQR MED is computer vision for the early detection of focal pathologies on MRI and CT imaging. We train the model on real clinical studies, transfer it together with usage rights, train the customer's clinical team, and operate the platform. First release — the liver model. In development — heart, pancreas, kidneys.
Liver cancer is one of the deadliest cancers worldwide — not because treatment is unavailable, but because most patients arrive too late. SAQR MED is built for that class of patient and that workflow, in any country where the diagnostic window is being missed.
Liver cancer generated 866,136 new cases and 758,725 deaths worldwide in 2022 — the 6th most-diagnosed cancer and the 3rd leading cause of cancer death.
Source: GLOBOCAN / IARC WHO 2022
With a mortality-to-incidence ratio of 0.86, liver cancer kills almost as many people as it diagnoses — a signature of late-stage discovery, not of untreatable biology.
Source: Chinese Medical Journal 2024
WHO estimates 240 million people are living with chronic HBV infection — the primary driver of hepatocellular carcinoma. A large, screenable at-risk population.
Source: WHO Hepatitis B fact sheet 2026
Almost 79% of the global liver-cancer burden falls on Asia and Africa. This is where late-stage presentation is most common — and where an early-window model has the highest clinical impact.
SAQR MED is a shipped software product for early visual diagnostics. We arrive not with a subscription or a device on regulatory approval, but with a trained model, the right to use it, and a team that helps the customer put it to work.
A CNN trained on ~8,700 real liver MRI studies. Certificate of developer rights. First release — liver; on the roadmap — heart, pancreas, kidneys.
The customer receives the model for permanent use — not a subscription seat. Weight files, configuration and documentation all sit inside the customer perimeter.
We train the customer's radiologists and IT engineers to operate the model, read risk maps and interpret results correctly. Not "give us access" — a full transfer of expertise.
We ship the platform that connects the model to the clinic's PACS/DICOM and radiologist workstations, operate it, and retrain the model as customer data accumulates.
SAQR MED sits next to the clinic's existing PACS. All inference happens locally — data never leaves the perimeter. The model produces a risk map for the radiologist, not an automated verdict.
An MRI or CT study is sent from the scanner or PACS to the local SAQR MED server. Standard DICOM format. No manual data preparation.
The CNN processes the slice series on a mini-PC next to the scanner. No cloud calls, no external APIs.
The result is not a binary "sick/well" alert but a visual map of attention regions on the study, ranked by probability of pathology.
The radiologist reads the risk map alongside the study and issues the report themselves. The model does not replace the physician — it shortens search time and reduces the probability of a miss.
Each new study is compared against the patient's prior studies. The model tracks changes in lesion size and structure between visits.
Four engineering choices that separate SAQR MED from generic AI services and from research prototypes.
The core is a convolutional neural network trained specifically on medical images. We do not take a general vision model and fine-tune it on a few hundred scans — the model is built from scratch for a specific anatomy.
~8,700 liver MRI studies from diagnostic clinics, regional hospitals, oncology centers and private practices. Not open datasets, not synthetic — real clinical material.
The model highlights regions that deserve the radiologist's attention and ranks them by probability. The physician reads the study — the model simply narrows the search space.
The model retains a patient's study series and highlights change between them — lesion size, density, morphology. Valuable on long clinical horizons.
We move deliberately from one anatomical zone to the next. Each model is trained separately, tested separately and delivered to the customer separately. No universal "model of everything".
First released version. Trained on ~8,700 MRI studies. Optimized for early hepatocellular lesions — a priority for countries with high HCC incidence.
A model for the early detection of myocardial and coronary pathologies on MRI and CT angiography. Expected release next after the liver model.
One of the hardest organs for early diagnostics. Focal changes are often missed until late stages. This model addresses exactly that gap.
A model for focal kidney lesions and their dynamics. Closes the set of four priority anatomical zones.
We name honestly what SAQR MED is not. That protects the clinic from wrong expectations, and us from wrong deployments.
SAQR MED is software that assists the radiologist. We do not position the product as a certified medical device and we do not replace the clinic's regulatory processes.
We do not target "tens of thousands of scans per day" routine studies. Our job is early detection of priority focal pathologies — not throughput.
The model runs on a local mini-PC inside the clinic perimeter. We do not collect patient data on our servers and do not send scans to third countries.
SAQR MED is not sold as SaaS. The customer receives the model and the rights to it, and pays for delivery and support — not a "seat in a system".
SAQR MED is transferred to the customer as a trained model with usage rights, together with deployment infrastructure and a training program for the team. Pricing is structured per project — figures are discussed individually.
| What is included | What the customer receives |
|---|---|
| Model | A trained CNN for the chosen anatomical zone with usage rights and full documentation. |
| Infrastructure | A local mini-PC with the model pre-installed, integrated with the clinic's existing PACS/DICOM system. |
| Team training | A training program for the customer's radiologists and IT engineers: interface work, risk-map interpretation, platform operations. |
| Support | 12 months of baseline support after go-live: SLA, updates, consultations, complex-case reviews. |
| Pilot | Option to start with a limited pilot on one clinical site, with subsequent expansion based on the outcome. |
Pricing is structured per project and discussed individually.
Request termsWe do not disclose the names of the medical scientific director or the partner clinics — this is a condition of working with clinical data. Below are the aggregate credentials of the team responsible for the product's clinical quality.
Name withheld — the scientific director works with several SAQR MED clinical partners, and their involvement is covered by confidentiality agreements. Available under NDA.
The team participates in training-data annotation, model validation and complex clinical-case reviews.
A full product team — not consulting, not outsourcing.
An example of how the model follows a single patient over time. Country, clinic and patient details are generalized — the scenario reflects a typical workflow.
Patient attends a routine liver exam. The model highlights a small focal area a radiologist might miss under case load. Follow-up is scheduled at 3 months.
The model compares the new study against baseline — the lesion has grown from ~8 mm to ~12 mm. An automated comparison map is generated. The physician initiates treatment.
On the third study, the model shows significant reduction — annotation moves to "marked shrinkage". Patient stabilizes under observation, therapy is working.
We break deployment into six measurable stages. Each ends with a concrete result — not with "exploring possibilities".
We assess the clinic's PACS system, hardware, data flows and country-specific regulatory requirements. Output — a technical scope.
We run the model on a representative sample of the clinic's anonymized studies. The customer sees the model on their own data before signing a contract.
Commercial terms, licensing rights and delivery scope are finalized. Mini-PC is shipped, model files are transferred.
Deployment on the clinical site, integration with PACS/DICOM, role-based access setup, test runs.
Training program for the customer's radiologists and IT engineers. Real clinical cases, risk-map interpretation, platform operations.
Planned SLA, model updates, complex-case reviews, consultations. The outcome informs the decision to move to the next anatomical zone.
We do not rely on "trust us" — the product architecture is built so that patient data physically does not leave the clinic.
The model and patient data sit on a mini-PC inside the clinic perimeter. No cloud calls, no scans on SAQR AI servers.
Radiologists, treating physicians and IT engineers only see what their role requires. Full permission segregation in the interface.
Every interaction with the model and its results is recorded: who opened a study, what finding the model returned, what decision the physician made.
The architecture is designed to be compatible with HIPAA (US), GDPR (EU) and regional data-protection frameworks. Specific compliance is contractual work with the individual clinic.
SAQR AI is a technology group building applied artificial intelligence for critical industries — energy, water, industry and medicine. We combine deep domain expertise with modern AI methods and take ownership of the customer's operational outcome.
SAQR EDGE — autonomous perception for critical infrastructure (solar, desalination, oil & gas, construction).
SAQR MED — computer vision for early visual diagnostics (liver, heart, pancreas, kidneys).
Each line has its own team, its own delivery model and its own regulatory path. A single brand and a shared engineering foundation.
All commercial relationships are conducted through an entity registered in the Kyrgyz Republic.
| Company | SAQR AI LLC |
|---|---|
| Registration number | 329540-3301-OOO |
| Tax ID (INN) | 00106202610099 |
| OKPO | 34970908 |
| Registered address | 141/1 Patrice Lumumba St., Bishkek, Kyrgyz Republic |
| Registration date | 1 June 2026, Chui-Bishkek Department of Justice |
| Director | Evgeny A. Korshunov |
We will discuss your clinical scenario, run the model on a representative sample of your data and propose a pilot scoped to a specific site.